Introduction
============

Allergic rhinitis (AR), a non-infectious disease of the nasal mucosa, is primarily mediated by immunoglobulin E (IgE) following contact with allergens ([@b1-ijmm-45-04-1150]). The self-reported prevalence of AR in 11 cities across Mainland China had wide variations in 2005, ranging between \<10 and \>20% ([@b2-ijmm-45-04-1150]); in 2011, the standardized prevalence of adult AR in the 18 major cities was 17.6%, with the highest prevalence of 23% in Shanghai and the lowest prevalence of 9.8% in Chengdu ([@b3-ijmm-45-04-1150]). The number of patients with AR in China has increased by 100 million between 2005 and 2011 ([@b4-ijmm-45-04-1150]). AR has traditionally been considered to originate from a T helper (Th)1/Th2 immune response imbalance, leading to allergic inflammation dominated by the Th2 immune response within the nasal mucosa ([@b5-ijmm-45-04-1150]). Following further study, the pathogenesis of AR has been extended from the Thl/Th2 model to a Thl/Th2/Thl7 and T regulatory cell (Treg) model ([@b6-ijmm-45-04-1150]). However, as AR is a multi-factor disease induced by gene-environment interactions, its exact pathogenesis has not been elucidated.

Lysine acetylation is a reversible post-transcriptional modification that regulates changes in gene expression profiles ([@b7-ijmm-45-04-1150]). Two opposing enzymes function intracellularly to determine protein acetylation levels; specifically, histone acetyltransferase (HAT) catalyzes the addition of an acetyl group to lysine residues, whereas histone deacetylase (HDAC) catalyzes the removal of an acetyl group from lysine residues ([@b7-ijmm-45-04-1150]). The HAT/HDAC balance maintains histone acetylation levels and regulates gene transcription ([@b8-ijmm-45-04-1150]). Redox signaling, which is mediated by HAT-induced inactivation of histone acetylation, decisively contributes to the activation phase of the inflammatory cascade ([@b9-ijmm-45-04-1150]). Targeting HAT Tip60 inhibits intestinal allergies in a mouse model ([@b10-ijmm-45-04-1150]). The expression of HDAC1, HDAC5, HDAC6 and HDAC8 increases in asthmatic mice ([@b11-ijmm-45-04-1150]); HDAC11 ([@b12-ijmm-45-04-1150]) and HDAC1 ([@b13-ijmm-45-04-1150]) expression levels are increased in patients with AR, and HDAC1 also participates in the pathogenesis of childhood asthma ([@b14-ijmm-45-04-1150]).

Sodium butyrate (NaB) is an aliphatic acid and a nonspecific HDAC inhibitor ([@b15-ijmm-45-04-1150]). The results of our previous study indicated that NaB nasal drops decreased the expression of HDAC1 and HDAC3 and increased histone H3 acetylation at lysine 9 (H3-AcK9) ([@b16-ijmm-45-04-1150]). Butyrate is the final product of the anaerobic fermentation of dietary fiber by intestinal microorganisms ([@b17-ijmm-45-04-1150]), and butyrate levels in stool samples from patients with atopic dermatitis have been demonstrated to be decreased ([@b18-ijmm-45-04-1150]). Oral NaB may modulate brain metabolism ([@b19-ijmm-45-04-1150]) and attenuate experimental murine colitis in an IL-10 independent manner ([@b20-ijmm-45-04-1150]).

The objective of the present study was to investigate the preventive effect of NaB on AR by adding it to the diet of newly weaned mice at 3 weeks of age and to determine the changes in lncRNA and mRNA expression profiles in the nasal mucosa following NaB treatment.

Materials and methods
=====================

Animals and trials
------------------

BALB/C mice (3 weeks old; 6-8 g) were purchased from the Air Force Military Medical University (Xi\'an, China). Mice were maintained in a pathogen-free environment under a 12/12-h light/dark cycle at 22°C with free access to food and water. All animal experiments were conducted in accordance with the National Institutes of Health guidelines and approved by the Committee on Animal Research of the Air Force Military Medical University (approval no. KJ-2016-XJB5436).

Mice were randomly divided into three groups (n=30 mice/group) as follows: i) Control (C) group (no treatment); ii) AR group \[treated with ovalbumin (OVA)\]; and iii) NaB + AR group (treated with OVA and NaB). Mice began to feed after weaning at 3 weeks of age. The mouse feed was premixed, 30 g/kg NaB (Sigma-Aldrich; Merck KGaA) was added, and granules were produced. Normal feed and NaB feed were provided by the Animal Center of the Air Force Medical University. Each mouse in the NaB + AR group consumed an average of 5 g feed/day, which contained 0.15 g NaB. The other 2 groups were provided with normal feed throughout the study period. At 7 weeks of age, mice in the AR and NaB + AR groups received intraperitoneal injections of mixed OVA solution (20 mg) and aluminum (2 mg) in 0.5 ml PBS on days 1, 3, 6 and 8, whereas the control mice received injections of aluminum (2 mg) in 0.5 ml PBS under the same schedule. Mice in the AR and NaB + AR groups were also treated with 10% OVA (20 *µ*l) via intranasal instillation once daily between days 15 and 24. Mice in the control group were treated with 20 *µ*l PBS via intranasal instillation once daily during the same period. [Fig. 1](#f1-ijmm-45-04-1150){ref-type="fig"} demonstrates the experimental design. One hour after the last challenge, mice were anesthetized (4% chloral hydrate, 400 mg/kg) and venous blood was obtained for use in ELISA \[mouse ELISA kits: IL-2 (cat. no. 223588), IL-4 (cat. no. 221833), IL-5 (cat. no. 204523), IL-17 (cat. no. 100702), interferon γ (IFN-γ; cat. no. 46107) and transforming growth factor-β1 (TGF-β1; cat. no. 119557); all from Abcam\]. Following blood sample collection, the mice were sacrificed by cervical dislocation, and the nasal mucosa was preserved in liquid nitrogen for further analysis.

Behavioral assessment
---------------------

Allergy symptoms were assessed using the following scoring criteria: 1 point for sneezing 1-3 times during a 30-min observation, clear nasal flow to the anterior nostril and occasional scratching of the nose with a single front limb; 2 points for sneezing 4-10 times, clear nasal flow beyond the nostril and scratching of the nose with both front limbs; and 3 points for sneezing \>10 times, clear nasal flow to the face and continuous scratching. After the last stimulation, each animal was observed for 30 min, and the three parameters were recorded and quantified. A total score \>5 points indicated that the model was successfully established ([@b21-ijmm-45-04-1150]).

Histological observation
------------------------

The muscle tissue of the nose was removed, and the nasal cavity was fixed in 4% formaldehyde for 24 h at 37°C. Following 10% EDTA decalcification for 24 h at 37°C, the nose was embedded in paraffin, and 4-*µ*m sections were cut. The sections (4-*µ*m) were dewaxed, stained with hematoxylin (cat. no. 245880; Abcam) for 10 min, differentiated with 1% hydrochloric acid ethanol for 1 min, stained with eosin for 1 min, dehydrated with a series of ethanol concentrations (70, 80, 90 and 100%) ethanol for 10 sec, incubated with xylene for 1 min and sealed. In addition, other sections were dewaxed, soaked with 3% acetic acid for 3 min, stained with 1% Alcian blue (cat. no. 150680; Abcam) for 30 min, soaked with 3% acetic acid for 3 min, washed with water, oxidized with 0.5% periodate for 10 min, soaked in Schiff\'s solution for 20 min and sealed.

Western blotting
----------------

Proteins were obtained from the nasal mucosa tissues of each mouse 1 h after the final intranasal administration of OVA or PBS. Proteins were extracted using a Protein Extraction kit (Applygen Technologies, Inc.), and total protein concentrations were measured using the Bio-Rad protein assay kit (Bio-Rad Laboratories, Inc.). A total of 20 *µ*g protein/lane was isolated by 12.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane (Bio-Rad Laboratories, Inc.). The membranes were blocked with 2.5% nonfat milk at 37°C for 1 h and incubated with anti-HDAC1 (mouse; 1:1,000; cat. no. 5356), anti-H3 (rabbit; 1:1,000; cat. no. 4499), anti-H3-AcK9 (rabbit; 1:1,000; cat. no. 9649S; all from Cell Signaling Technology, Inc.), anti-HDAC8 (rabbit; 1:1,000; cat. no. 187139; Abcam) and anti-GAPDH (mouse; 1:1,000; cat. no. 686613; R&D Systems, Inc.) antibodies overnight at 4°C. Following exposure to horseradish peroxidase-conjugated anti-mouse and anti-rabbit IgG secondary antibodies (1:200; Sigma-Aldrich; Merck KGaA) for 1 h at 37°C, immunoreactive bands were detected using an enhanced chemiluminescence western blotting system (Thermo Fisher Scientific, Inc.).

RNA microarray
--------------

The CapitalBio Technology Mouse LncRNA Array v1 was designed with four identical arrays per slide (4X180K format), with each array containing probes for 58,809 mouse lncRNAs and 39,027 mouse mRNAs. The lncRNA and mRNA target sequences were obtained by merging the results from multiple databases, including NCBI RefSeq (<https://www.ncbi.nlm.nih.gov/>), Ensembl (<http://asia.ensembl.org/index.html>), UCSC (<http://www.genome.ucsc.edu/>), FANTOM (<https://fantom.org/>), LncRNAdb (<http://live.dbpedia.org/page/LncRNAdb/>), NO NCODE V4.0 (<http://www.noncode.org/>), UCR (<https://www.ucr.edu/>), LncRNA Disease (<http://www.cuilab.cn/lncrnadisease>) and [LncRNA.org](http://LncRNA.org) (<https://lncipedia.org/>). Each RNA was detected by probes based on ≥2 replicates. The array also contained 4,974 Agilent control probes.

RNA extraction, amplification, labeling and hybridization
---------------------------------------------------------

The microarray assay was performed by Capital Biotech Corporation (Beijing, China) with the Agilent mouse lncRNA + mRNA Array V4.0 (4X180K) (Agilent Technologies, Inc.) according to the manufacturer\'s instructions. Total RNA was extracted using TRIzol^®^ reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s instructions. Briefly, 200 ng purified RNA from each sample was amplified and reverse-transcribed into cDNA. The cDNAs were transcribed into cRNAs at 70°C for 5 min, 25°C for 5 min and 4°C for 2 min, and the cRNAs were transcribed into cDNAs using the WT Expression Kit (cat. no. 4411973; Thermo Fisher Scientific, Inc.) at 70°C for 5 min, 25°C for 5 min and 4°C for 2 min, labeled with a fluorescent dye (Cy3-dCTP, Agilent Technologies, Inc.), denatured at 95°C for 3 min and incubated in an ice bath for 5 min. Labeled cDNAs were hybridized onto a Crystal core human lncRNA chip V4.0. The microarray data analyzed in the present study have been deposited in the NCBI GEO database under the accession number GSE140454.

Microarray imaging and data analysis
------------------------------------

The lncRNA and mRNA array data were analyzed for data summarization, normalization and quality control using Gene Spring software V12.0 (Agilent Technologies, Inc.). To identify the differentially expressed genes, the threshold values of fold-change ≥2 and ≤−2 and a Benjamini-Hochberg corrected P-value \<0.05 were used. The data were log~2~-transformed and median-centered on genes using the \'Adjust Data\' function of CLUSTER 3.0 software (Michiel de Hoon, University of Tokyo, Human Genome Center) prior to further analysis via hierarchical clustering with average linkage. Tree visualization was performed using Java Treeview 3.0 (Stanford University School of Medicine).

RNA isolation and reverse transcription-quantitative PCR (RT-qPCR)
------------------------------------------------------------------

Total RNA was extracted using TRIzol^®^ reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s instructions. The concentration, quality and purity of RNA were assessed using the RNA 6000 Nano assay on the Agilent 2100 Bioanalyzer (Agilent Technologies, Inc.). No samples exhibited RNA degradation (ratio of 28S:18S ribosomal RNA ≥2) or contamination with DNA. For reverse transcription, samples were incubated in an Eppendorf PCR system at 42°C for 30 min, 90°C for 5 min and 5°C for 5 min. The samples were subjected to qPCR with specific primers ([Table SI](#SD1-ijmm-45-04-1150){ref-type="supplementary-material"}). qPCR was performed in a 10 *µ*l total volume containing 1 *µ*l cDNA, 5 *µ*l SYBR^®^ Green Real-time PCR Master Mix (Toyobo Life Science) and 1 *µ*l of each primer under the following conditions: 95°C for 10 sec at; 40 cycles of 60°C for 5 sec and 72°C for 10 sec; and 65°C for 30 sec. Melting analysis of PCR products was conducted to validate the amplification of a specific product, and the relative fold-change was calculated using the 2^−∆∆Cq^ method normalized to GAPDH ([@b22-ijmm-45-04-1150]).

LncRNA-mRNA co-expression and construction of the coding-non-coding gene co-expression network
----------------------------------------------------------------------------------------------

Differentially expressed mRNAs were used to construct a co-expression network to explore specific lncRNAs involved in the pathogenesis of AR. Pearson correlation coefficients (PCCs) were calculated between selected mRNAs and all differentially expressed lncRNAs. A PCC ≥0.99 indicated that the selected lncRNA and mRNA formed a significantly correlated pair.

The coding-non-coding gene co-expression network was constructed based on the correlation analysis between differentially expressed lncRNAs and mRNAs. Significantly correlated pairs (based on PCC) were selected to construct the network. LncRNAs and mRNAs with PCCs ≥0.99 were selected to draw the network using the open-source bioinformatics software Cytoscape 3.7.2 (<https://cytoscape.org/>). For network analysis, a degree of centrality was defined as the number of links that one node had to others.

Prediction of cis-acting and trans-acting lncRNA
------------------------------------------------

The prediction of cis-acting lncRNA was performed based on a strong correlation between the lncRNA and a group of expressed protein-coding genes (PCC ≥0.99). The lncRNAs were only selected if they resided at the genomic loci where a protein-coding gene and an lncRNA gene were within 10 kb of each other along the genome; \'cis\' therefore refers to the same locus (not necessarily the same allele) regulatory mechanism, which included the antisense-mediated regulation of protein-coding genes by lncRNAs that in the same locus.

The trans-prediction was conducted using a Standalone BLAT v. 35 × 1 fast sequence search command line tool (<http://hgdownload.cse.ucsc.edu/admin/exe/>) to compare the full sequence of the lncRNA to the 3′-untranslated region of its co-expressed mRNAs using default parameter settings.

Analysis of Gene Ontology (GO) and PANTHER pathways
---------------------------------------------------

The functions of biological processes differentially expressed geneswere identified by GO analysis (<http://geneontology.org/>). The differentially expressed mRNAs were analyzed using PANTHER analysis (<http://pantherdb.org/>).

Statistical analysis
--------------------

Data are presented as the means ± SD. Analyses were performed using SPSS version 13.0 (SPSS, Inc.). Unpaired Student\'s t-test was used to identify differences between two groups. One-way ANOVA followed by the least significant difference test was used to compare multiple groups. Analysis of mRNA, lncRNA and RT-qPCR fold-change data were performed by Student\'s t-test using Microsoft Excel 15.17 (Microsoft Corporation). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Oral NaB decreases the AR-related behavioral score and improves nasal mucosal morphology
----------------------------------------------------------------------------------------

NaB treatment decreased the behavioral scores of mice with AR ([Fig. 2A](#f2-ijmm-45-04-1150){ref-type="fig"}). In addition, mice fed NaB for 7 weeks did not experience diarrhea or other adverse effects and gained weight normally ([Fig. 2B](#f2-ijmm-45-04-1150){ref-type="fig"}). Epithelial cells of the nasal mucosa in the AR group exhibited loss of cilia, edema of the sub-mucosal tissue, small vessel proliferation, infiltration of eosinophils ([Fig. 2C](#f2-ijmm-45-04-1150){ref-type="fig"}) and exuberant secretion of goblet cells ([Fig. 2D](#f2-ijmm-45-04-1150){ref-type="fig"}). NaB treatment reduced nasal mucosal inflammation in AR mice ([Fig. 2C and D](#f2-ijmm-45-04-1150){ref-type="fig"}). These results indicated that NaB could prevent AR, and that 7 weeks of NaB feeding did not affect mouse growth.

NaB rebalances Th1/Th2/Thl7 and Treg ratios in AR mouse mucosa
--------------------------------------------------------------

Following treatment of AR mice with NaB, serum ELISA demonstrated that the expression of IL-2 (a marker of Th1), IFN-γ (a marker of Th1) and TGF-β1 (a marker of Treg) was higher, whereas the levels of IL-4 (a marker of Th2), IL-5 (a marker of Th2) and IL-17 (a marker of Th17) were lower in the NaB + AR group compared with that in the AR group. These results indicated that NaB could restore Thl/Th2/Thl7 and Treg balance in AR mice ([Fig. 3](#f3-ijmm-45-04-1150){ref-type="fig"}).

NaB normalizes the AR-induced downregulation of H3-AcK9 and upregulation of HDAC1 and HDAC8 expression in mouse mucosa
----------------------------------------------------------------------------------------------------------------------

NaB partially reversed the downregulation of H3-AcK9 and upregulation of HDAC1 and HDAC8 expression induced by AR in the nasal mucosa of mice ([Fig. 4](#f4-ijmm-45-04-1150){ref-type="fig"}). These results suggested that NaB could restore the HDAC/HAT balance.

Differences in lncRNA and mRNA expression profiles in the nasal mucosa among the three groups
---------------------------------------------------------------------------------------------

A scatter function was used to identify the differences in lncRNA and mRNA expression (log~2~ expression value) among the three groups. LncRNA analysis demonstrated that compared with the expression levels in the C group, 254 genes were upregulated and 109 were downregulated in the AR group, and 18 genes were upregulated and 47 were downregulated in the NaB + AR group. Compared with the AR group, 32 genes were upregulated and 230 were downregulated in the NaB + AR group ([Fig. 5A](#f5-ijmm-45-04-1150){ref-type="fig"}). mRNA analysis revealed that compared with the expression levels in the C group, 319 genes were upregulated and 524 were downregulated in the AR group, and 159 genes were upregulated and 218 were downregulated in the NaB + AR group. Compared with the AR group, 114 genes were upregulated and 45 were downregulated in the NaB + AR group ([Fig. 5B](#f5-ijmm-45-04-1150){ref-type="fig"}).

LncRNA (NONMMUT057309), lncRNA (NONMMUT016103) ([Table I](#tI-ijmm-45-04-1150){ref-type="table"}) and 33 mRNAs ([Table II](#tII-ijmm-45-04-1150){ref-type="table"}) were identified to be co-expressed, and expression trends for these markers were consistent among the C, AR and NaB + AR groups. The 33 mRNAs encoded immunoglobulins, suggesting that lncRNA may regulate the expression of immunoglobulins during AR inflammation.

RT-qPCR validation of microarray data
-------------------------------------

Statistically significant differences were identified at four mRNA (A-65-P07626, A-52-P50284, A-66-P10323 and A-55-P21872) and two lncRNA (NONMMUT016103 and NONMMUT057309) loci between C vs. AR, NaB + AR vs. AR and NaB + AR vs. C groups in the microarray results. RT-qPCR validation results in the three groups were consistent with the micro-array analysis results, with the exception of the lncRNA (NUNMMUT016103) locus ([Fig. 6](#f6-ijmm-45-04-1150){ref-type="fig"}).

LncRNA (NONMMUT057309)-mRNA co-expression analysis
--------------------------------------------------

LncRNA (NONMMUT057309) co-expression analysis of mRNA (data not shown) and target gene prediction ([Fig. 7](#f7-ijmm-45-04-1150){ref-type="fig"}) revealed that only three target genes of lncRNA (NONMMUT057309) \[octamer-binding transcription factor 1 (Oct-1), ecotropic viral integration site 1 (Evi-1) and paired box 4 (Pax-4)\] were predicted between NaB + AR vs. AR, NaB + AR vs. C and AR vs. C groups.

GO and PANTHER pathway analyses
-------------------------------

GO analysis was conducted to determine the enrichment of the differentially expressed mRNAs between the different groups in the categories of biological processes. The top 10 significantly enriched GO terms between each pair of groups are presented in [Fig. 8](#f8-ijmm-45-04-1150){ref-type="fig"}.

Pathway analysis was conducted to determine the biological pathways represented by the significantly differentially expressed mRNAs between the groups. The top 10 significantly enriched PANTHER pathway terms among the three groups are presented in [Fig. 9](#f9-ijmm-45-04-1150){ref-type="fig"}. Based on these results, inflammation mediated by chemokine and cytokine signaling pathways and T-cell activation were suggested to be involved in AR pathogenesis.

Discussion
==========

HDAC inhibitors can be divided into four categories, including hydroxamates, cyclic peptides, aliphatic acids and benzamides. Suberoylanilide hydroxamic acid (SAHA) has been approved by the US Food and Drug Administration for the treatment of cutaneous T-cell lymphoma ([@b7-ijmm-45-04-1150]). HDAC inhibitors have also been demonstrated to exhibit therapeutic effects in cancer, arthritis, hearing loss and asthma ([@b23-ijmm-45-04-1150]-[@b27-ijmm-45-04-1150]). Since epigenetic modifications, which contribute to disease development, are neither permanent nor transient, identifying disease-specific epigenetic alterations may help identify novel therapeutic interventions ([@b28-ijmm-45-04-1150],[@b29-ijmm-45-04-1150]). NaB can be dissolved without dimethyl sulfoxide, which is a solvent that also inhibits HDAC, thus enabling the sole evaluation of NaB and its effects ([@b30-ijmm-45-04-1150],[@b31-ijmm-45-04-1150]). The results of our previous study demonstrated that NaB exhibited a therapeutic effect in an OVA-induced murine AR model when administered intranasally ([@b16-ijmm-45-04-1150]). The present study demonstrated that oral NaB for 7 weeks did not result in any adverse effects, and animals gained weight normally. In addition, a previous study revealed that NaB enhanced intestinal integrity in weaned pigs ([@b32-ijmm-45-04-1150]). Adding NaB increased the food intake of lactating sows and improved the growth of piglets ([@b33-ijmm-45-04-1150]). In the present study, NaB prophylactically reduced AR-related behavioral scores, improved nasal mucosal morphology and restored Th1/Th2/Thl7 and Treg cell balance. Thus, NaB may exhibit a preventive effect on AR. The present study demonstrated that NaB increased H3-AcK9 expression and decreased of HDAC1 and HDAC8 expression in mice with AR. Accordingly, high HDAC1 and HDAC8 expression levels have been observed in OVA-sensitized asthmatic mice ([@b11-ijmm-45-04-1150]). In addition, an HDAC8-specific inhibitor was demonstrated to reduce the eosinophil-mediated inflammatory response and reduce the sensitivity of the airway in an asthma model ([@b34-ijmm-45-04-1150]). Therefore, blocking HDAC activity may be a novel therapeutic target in patients with AR ([@b7-ijmm-45-04-1150]).

LncRNA regulates gene expression at the transcriptional, RNA processing and translational levels ([@b35-ijmm-45-04-1150]). In addition, lncRNA dysregulation underlies certain human diseases caused by chromosome deletion and translocation ([@b36-ijmm-45-04-1150]). LncRNAs are also involved in the development, plasticity, disease and evolution of the mammalian nervous system ([@b37-ijmm-45-04-1150]). LncRNAs can promote the differentiation and activation of dendritic cells, B lymphocytes and T lymphocytes ([@b38-ijmm-45-04-1150]). Accordingly, a number of specific lncRNAs have been identified in Th1 and Th2 cells ([@b39-ijmm-45-04-1150]-[@b42-ijmm-45-04-1150]) and in the nasal mucosa of mice with AR ([@b3-ijmm-45-04-1150]). The results of the present study confirmed the differential expression of lncRNAs and mRNAs in the nasal mucosa of AR mice treated with NaB. A degree is the simplest and most important measure of gene centrality within a network that determines the relative importance of that gene ([@b43-ijmm-45-04-1150]). LncRNA (NONMMUT057309), which is 306 nt long and located on chromosome 6, is mainly expressed in the hippo-campus, liver, and lung ([@b44-ijmm-45-04-1150]); however, to the best of our knowledge, no published studies on the mechanism associated with its function are currently available.

NaB, a pan-HDAC inhibitor, not only decreased the expression of HDAC1 and HDAC8, but also downregulated the expression of lncRNA (NONMMUT057309) and altered the expression of immunoglobulins in the present study. Previous studies have demonstrated that HDAC and lnc-H19 could be bidirectionally regulated ([@b45-ijmm-45-04-1150]), and the pan-HDAC inhibitors panobinostat and SAHA upregulated lnc-GAS5 expression in non-small cell lung cancer ([@b46-ijmm-45-04-1150]). Thus, it may be speculated that NaB could influence the nasal mucosa allergic response through lncRNA (NONMMUT057309) expression. LncRNA (NONMMUT057309) may act on its target genes to regulate the expression of immunoglobulin in the nasal mucosa to prevent AR.

Three target genes (Oct-1, Evi-1 and Pax-4) were predicted for lncRNA (NONMMUT057309). Oct-1 can co-regulate Th2 cytokine gene expression through Rhs-related transmembrane protein ([@b47-ijmm-45-04-1150]) and regulate the expression of IL-17 ([@b48-ijmm-45-04-1150]). Evi-1 participates in the pathogenesis of colorectal cancer through TGF-β signaling ([@b49-ijmm-45-04-1150]). The duodenum of functional dyspepsia rats displayed increased expressions of PAX4 ([@b50-ijmm-45-04-1150]).

Among the top 10 significantly enriched GO terms in C vs. AR groups, \'extracellular matrix organization\' has been determined to exert effects on airway epithelial cells and fibroblast structure ([@b51-ijmm-45-04-1150]). The regulation of the immune system in early life by the microbiota may be associated with allergy development ([@b52-ijmm-45-04-1150]). The pathology of bronchial asthma demonstrates a multicellular process ([@b53-ijmm-45-04-1150]). AR rats exhibit microvascular remodeling of the nasal mucosa ([@b54-ijmm-45-04-1150]). In the top 10 significantly enriched GO terms in NaB + AR vs. AR groups, salmon cartilage proteoglycan attenuates allergic responses in mice ([@b55-ijmm-45-04-1150]). Inhibiting platelet activating factor can treat AR ([@b56-ijmm-45-04-1150]). Among top 10 significantly enriched GO terms in NaB+AR vs. C groups, immunoglobulin E (lgε) receptor on lymphocyte γ chain can mediate the receptor activator for NF-κB ligand, which is the primary cytokine required for osteoclastogenesis ([@b57-ijmm-45-04-1150]). ROS likely originates from inflammatory cells (eosinophils, neutrophils and macrophages), and their deleterious activity can result in oxidative DNA damage ([@b58-ijmm-45-04-1150]). Maternal exposure to any type of stressor is associated with an increased risk of an atopic offspring ([@b59-ijmm-45-04-1150]). There are important connections between hemopoiesis and allergy/asthma ([@b60-ijmm-45-04-1150]). Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity ([@b61-ijmm-45-04-1150]). In patients with asthma, serum endotoxin concentrations significantly correlate with sputum chemokine motif ligand 2 concentrations ([@b62-ijmm-45-04-1150]).

The present study also determined the top 10 PANTHER pathways represented by the differentially expressed genes. \'T-cell activation\', \'B cell activation\', \'Interleukin signaling pathway\', \'Inflammation mediated by chemokine and cytokine signaling pathway\' and \'Histamine H2 receptor mediated signaling pathway\' participate in allergic inflammation ([@b4-ijmm-45-04-1150],[@b63-ijmm-45-04-1150]-[@b64-ijmm-45-04-1150]). \'Apoptosis signaling pathway\' ([@b65-ijmm-45-04-1150]) and \'Toll receptor signaling pathway\' ([@b66-ijmm-45-04-1150]) are also involved in the pathology of AR. The expression of endotherin 2 is increased in cigarette-exposed asthmatic mice ([@b67-ijmm-45-04-1150]). Heme oxygenase-1 protects airway epithelium against apoptosis by targeting the proinflammatory NLRP3-RXR axis in asthma ([@b68-ijmm-45-04-1150]). Fibroblast-specific integrin-α V differentially regulates type 17 and type 2 driven inflammation and fibrosis ([@b69-ijmm-45-04-1150]). The p38 MAP-kinase pathway is involved in the production of chloride voltage-gated channel 3 in nasal epithelial AR cells induced by IL-4 ([@b70-ijmm-45-04-1150]). The Wnt signaling pathway has also been demonstrated to be differentially regulated in patients with AR ([@b71-ijmm-45-04-1150]). TGF-β/Smad signaling is involved in allergic diseases ([@b72-ijmm-45-04-1150]-[@b74-ijmm-45-04-1150]). At present, to the best of our knowledge, no reports are available on the gonadotropin-releasing hormone receptor, succinate to proportionate conversion or angiotensin H-stimulated signaling through G proteins and β-arrestin involvement in allergic inflammation pathogenesis, which is worth further study.

Together, previous findings along with the results of the present study may provide new options for the treatment of AR. However, in the present study, the gene sample was small, and further *in vitro* experiments are needed to further verify the role of lncRNA (NONMMUT057309), as well as the target genes (Oct-1, Evi-1, Pax-4) and signaling pathways, in the prevention of AR in the nasal mucosa of NaB-treated mice.
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![Experimental design. NaB, sodium butyrate; OVA, ovalbumin; ip, intraperitoneal injection; w, week.](IJMM-45-04-1150-g00){#f1-ijmm-45-04-1150}

![NaB improves symptoms of allergic rhinitis in a mouse model. (A) In the AR group, the behavioral scores were higher compared with the C group. NaB treatment decreased the behavioral scores in the NaB + AR group compared with those in the AR group, although significant differences in behavioral scores were present between the C and NaB + AR groups. (B) The average bodyweight in the AR group was significantly lower compared with the C and NaB + AR groups. No significant differences were observed between the bodyweights in the C and NaB + AR groups. (C) Hematoxylin and eosin staining of epithelial cells of the nasal mucosa in the AR group revealed loss of cilia, edema of sub-mucosal tissue, proliferation of small vessels and infiltration of eosinophils. (D) Alcian blue staining demonstrated exuberant secretion by goblet cells. The NaB + AR group exhibited less cilia loss, edema of sub-mucosal tissue, proliferation of small vessels, infiltration of eosinophils and secretion of goblet cells compared with the AR group. Data are presented as the mean ± SD. \*P\<0.05. NaB, sodium butyrate; C, control group; AR, rats treated with ovalbumin; NaB + AR, rats treated with NaB and ovalbumin.](IJMM-45-04-1150-g01){#f2-ijmm-45-04-1150}

![Serum ELISA results of IL-2, IFN-γ, TGF-β1, IL-4, IL-5 and IL-17. The expression levels of IL-2, IFN-γ and TGF-β1 were lower, whereas those of IL-4, IL-5 and IL-17 were higher in the AR group compared with the C group. NaB treatment increased the expression of IL-2, IFN-γ and TGF-β1 and decreased the expression of IL-4, IL-5 and IL-17 compared with the AR group, although significant differences in ELISA results were present between the C and NaB + AR groups. Data are presented as the mean ± SD. ^\*^P\<0.05. IL, interleukin; INF-γ, interferon γ; TGF-β1, transforming growth factor β1; NaB, sodium butyrate; C, control group; AR, rats treated with ovalbumin; NaB + AR, rats treated with NaB and ovalbumin.](IJMM-45-04-1150-g02){#f3-ijmm-45-04-1150}

![The protein levels of HDAC1, HDAC8 and H3-AcK9 in mouse nasal mucosa detected by western blot analysis. The expression of HDAC1 and HDAC8 increased, whereas that of H3-AcK9 decreased in the AR group compared with the C group. NaB treatment decreased the expression of HDAC1 and HDAC8 and increased the expression of H3-ACK9, although significant differences were still present in the western blot analysis results between the C and NaB + AR groups. Data are presented as the mean ± SD. ^\*^P\<0.05. HDAC, histone deacetylase; H3-AcK9, histone H3 acetylated at lysine 9; NaB, sodium butyrate; C, control group; AR, rats treated with ovalbumin; NaB + AR, rats treated with NaB and ovalbumin.](IJMM-45-04-1150-g03){#f4-ijmm-45-04-1150}

![Transcriptomic analysis of expression differences among the treatment groups. (A) Long non-coding RNA analysis. (B) mRNA analysis. Red indicates upregulated genes; green indicates downregulated genes. C, control group; AR, rats treated with ovalbumin; NaB + AR, rats treated with sodium butyrate and ovalbumin.](IJMM-45-04-1150-g04){#f5-ijmm-45-04-1150}

![Comparison of lncRNA and mRNA fold-change measured by microarray and RT-qPCR. RT-qPCR validation results among the three groups were consistent with the microarray analysis results, with the exception of the lncRNA (NUNMMUT016103) locus. Microarray results are represented by blue bars; RT-qPCR results are represented by red bars. ^\*^P\<0.05, ^\*\*^P\<0.01. LncRNA, long non-coding RNA; RT-qPCR, reverse transcription-quantitative PCR; C, control group; AR, rats treated with ovalbumin; NaB + AR, rats treated with sodium butyrate and ovalbumin.](IJMM-45-04-1150-g05){#f6-ijmm-45-04-1150}

![LncRNA (NONMMUT057309) target gene prediction. Oct-1, Evi-1, and Pax-4 were predicted between NaB+AR vs. AR, NaB + AR vs. C and AR vs. C groups of lncRNA (NONMMUT057309). LncRNA, long non-coding RNA; Oct-1, octamer-binding transcription factor 1; Evi-1, ecotropic viral integration site 1; Pax-4, paired box 4.](IJMM-45-04-1150-g06){#f7-ijmm-45-04-1150}

![Top 10 significantly enriched GO terms in each of the compared groups. GO, Gene Ontology; C, control group; AR, rats treated with ovalbumin; NaB + AR, rats treated with sodium butyrate and ovalbumin.](IJMM-45-04-1150-g07){#f8-ijmm-45-04-1150}

![Top 10 significantly enriched PANTHER pathways in each of the compared groups. C, control group; AR, rats treated with ovalbumin; NaB + AR, rats treated with sodium butyrate and ovalbumin.](IJMM-45-04-1150-g08){#f9-ijmm-45-04-1150}

###### 

LncRNA (NONMMUT057309) and lncRNA (NONMMUT016103) expression trends among the C, AR, and NaB + AR groups.

  LncRNA          Chr   Gene ID            NaB + AR vs. C   NaB + AR vs. AR   C vs. AR                                            
  --------------- ----- ------------------ ---------------- ----------------- ---------- ------ --------- ------ ------ --------- ----
  NONMMUT016103   12    NONMMUG0 10108.2   0.04             3.8545            Up         0.04   11.5375   Down   0.01   44.4719   Up
  NONMMUT057309   6     NONMMUG0 35579.2   0.03             2.4944            Up         0.04   4.9847    Down   0.01   12.4342   Up

LncRNA, long non-coding RNA; chr, chromosome; \|FC\|, absolute fold-change; C, control group; AR, rats treated with ovalbumin; NaB + AR, rats treated with ovalbumin and sodium butyrate.

###### 

Co-expressed mRNAs encoding immunoglobulins (n=33) among the C, AR, and NaB + AR groups.

  mRNA            Description                                                                                  ID
  --------------- -------------------------------------------------------------------------------------------- --------------------
  A_52_P382676    Immunoglobulin heavy variable 6-6 \[Source:MGI Symbol;Acc:MGI:4439619\]                      ENSMUST00000103489
  A_55_P2001269   Immunoglobulin heavy variable 1-52 \[Source:MGI Symbol;Acc:MGI:4439752\]                     ENSMUST00000103522
  A_55_P2046653   Immunoglobulin heavy variable 2-9 \[Source:MGI Symbol;Acc:MGI:4439624\]                      ENSMUST00000103451
  A_55_P2060897   Immunoglobulin kappa constant \[Source:MGI Symbol;Acc:MGI:96495\]                            ENSMUST00000103410
  A_66_P114582    Immunoglobulin heavy variable V1-54 \[Source:MGI Symbol;Acc:MGI:3647133\]                    ENSMUST00000103525
  A_55_P2001274   Immunoglobulin heavy variable 1-62-3 \[Source:MGI Symbol;Acc:MGI:3648544\]                   ENSMUST00000103532
  A_55_P2130497   Immunoglobulin heavy variable V1-67 \[Source:MGI Symbol;Acc:MGI:3645228\]                    ENSMUST00000103538
  A_55_P2030299   Immunoglobulin heavy variable V14-3 \[Source:MGI Symbol;Acc:MGI:4439764\]                    ENSMUST00000103469
  A_55_P1993001   Immunoglobulin heavy variable 1-55 \[Source:MGI Symbol;Acc:MGI:4439716\]                     ENSMUST00000103526
  A_55_P2058621   Mus musculus clone J558.2 immunoglobulin heavy chain variable region mRNA, partial cds       AF303833
  A_52_P15966     Immunoglobulin heavy variable 1-84 \[Source:MGI Symbol;Acc:MGI:3644235\]                     ENSMUST00000103551
  A_65_P07626     Immunoglobulin kappa variable 3-2 \[Source:MGI Symbol;Acc:MGI:1330850\]                      ENSMUST00000103403
  A_55_P2187234   Immunoglobulin heavy variable 2-2 \[Source:MGI Symbol;Acc:MGI:4439894\]                      ENSMUST00000103443
  A_55_P2052913   Immunoglobulin heavy variable 5-9 \[Source:MGI Symbol;Acc:MGI:4439873\]                      ENSMUST00000103448
  A_55_P1979364   Immunoglobulin heavy variable 1-83 \[Source:MGI Symbol;Acc:MGI:3648939\]                     ENSMUST00000103550
  A_55_P2159911   Immunoglobulin heavy variable 2-3 \[Source:MGI Symbol;Acc:MGI:4439872\]                      ENSMUST00000178229
  A_52_P320761    Immunoglobulin heavy variable 1-31 \[Source:MGI Symbol;Acc:MGI:4439889\]                     ENSMUST00000103511
  A_55_P2026268   Immunoglobulin kappa chain variable 5-43 \[Source:MGI Symbol;Acc: MGI:4943320\]              ENSMUST00000103368
  A_52_P213483    Immunoglobulin heavy variable 1-77 \[Source:MGI Symbol;Acc:MGI:4439670\]                     ENSMUST00000170551
  A_55_P1969901   Immunoglobulin heavy variable 1-80 \[Source:MGI Symbol;Acc:MGI:4439738\]                     ENSMUST00000103547
  A_52_P502849    Immunoglobulin kappa variable 3-4 \[Source:MGI Symbol;Acc:MGI:1330855\]                      ENSMUST00000103401
  A_51_P461067    Immunoglobulin heavy constant gamma 1 \[Source:MGI Symbol;Acc: MGI:96446\]                   ENSMUST00000103420
  A_55_P1970464   Immunoglobulin heavy variable 1-22 \[Source:MGI Symbol;Acc:MGI:4439784\]                     ENSMUST00000103507
  A_55_P2155560   Immunoglobulin heavy variable V1-5 \[Source:MGI Symbol;Acc:MGI:3704121\]                     ENSMUST00000103494
  A_55_P2134277   Immunoglobulin heavy variable V1-18 \[Source:MGI Symbol;Acc:MGI:4439780\]                    ENSMUST00000103504
  A_66_P103232    Immunoglobulin kappa chain variable 5-45 \[Source:MGI Symbol;Acc: MGI:4439774\]              ENSMUST00000103366
  A_55_P2065506   Immunoglobulin heavy variable 1-36 \[Source:MGI Symbol;Acc:MGI:4439639\]                     ENSMUST00000103513
  A_55_P2129334   Mus musculus clone L2MZB-13.3 immunoglobulin heavy chain variable region mRNA, partial cds   AY171990
  A_55_P2138627   Immunoglobulin heavy variable 6-3 \[Source:MGI Symbol;Acc:MGI:4439854\]                      ENSMUST00000103486
  A_55_P2164784   Immunoglobulin heavy variable 2-5 \[Source:MGI Symbol;-Acc:MGI:4439517\]                     ENSMUST00000103449
  A_66_P104923    Immunoglobulin heavy variable 1-81 \[Source:MGI Symbol;Acc:MGI:4439635\]                     ENSMUST00000103548
  A_51_P390937    Immunoglobulin kappa variable 14-111 \[Source:MGI Symbol;Acc:MGI:4439863\]                   ENSMUST00000103320
  A_55_P2187235   Immunoglobulin heavy variable 2-2 \[Source:MGI Symbol;Acc:MGI:4439894\]                      ENSMUST00000103443

MGI is the international database resource for the laboratory mouse, providing integrated genetic, genomic, and biological data to facilitate the study of human health and disease. C, control group; AR, rats treated with ovalbumin; NaB + AR, rats treated with both ovalbumin and sodium butyrate.

[^1]: Contributed equally
